Rapport Therapeutics, Inc. Common Stock (RAPP NASDAQ) stock market data APIs
$28.7838
-1.02(-3.5%)
as of February 17, 2026
Try our APIs with
free plan!
Rapport Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Prev. Close
28.7838
Open
27.7625
High
30.092
Low
27.2356
52 wk Range
6.43-42.269
Market Cap
1 331 M
Shares Outstanding
47 661 K
EPS
-0.71
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Rapport Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Rapport Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Rapport Therapeutics, Inc. Common Stock Fundamental Data
Rapport Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -109 099 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.732
Get Rapport Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rapport Therapeutics, Inc. Common Stock News
New
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents...
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents...
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rapport Therapeutics, Inc. BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology compa...
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients�...
Get Rapport Therapeutics, Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
